Synapse - Julie Feldstein

Results (298)

Risk-adapted intravenous melphalan with adjuvant thalidomide and dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis: Interim report of a phase II trial

Conference Paper

Comenzo, R. L.; Zhou, P.; Reich, L.; Costello, S.; Quinn, A.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; more...
CRC Press (2004)

Fulltext@MSK | Save

The importance of molecular phenotype in predicting overall survival in patients with relapsed or primary refractory DLBCL treated with second-line chemotherapy and ASCT

Meeting Abstract

Moskowitz, C. H.; Kewalramani, T.; Hamlin, P.; Nimer, S. D.; Zelenetz, A. D.; Teruya-Feldstein, J.
Blood (2004)

Fulltext@MSK | Save

POKEMON is a proto-oncogene which plays a key role in lymphomagenesis

Meeting Abstract

Maeda, T.; Hobbs, R.; Merghoub, T.; Guernah, I.; Zelent, A.; Teruya-Feldstein, J.; Pandolfi, P. P.
Blood (2004)

Fulltext@MSK | Save

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma

Meeting Abstract

Hassoun, H.; Reich, L.; Klimek, V. M.; Kewalramani, T.; Dhodapkar, M.; Drake, L.; Zimman, R.; Hedvat, C. V.; Teruya-Feldstein, J.; Fleisher, M.; more...
Blood (2004)

Fulltext@MSK | Save

The follicular lymphoma international prognostic index (FLIPI) is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma

Meeting Abstract

Halaas, J. L.; Teruya-Feldstein, J.; Filippa, D. A.; Moskowitz, C.; Naresh, K. N.; Zelenetz, A. D.
Blood (2004)

Fulltext@MSK | Save

Risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL): Interim results of a phase II study